Clinical Trial

Evaluation of MTX-439 in Healthy Adults and Adults With Diabetic Kidney Disease

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a phase 1 randomized, double-blind, single ascending dose (SAD) and multiple ascending dose (MAD) study to assess the safety, tolerability, and Pharmacokinetics (PK) of single and multiple ascending doses of MTX-439 administered in healthy adults and adults with diabetic kidney disease (DKD)
Protocol Amendment History 1 change
critical Recruitment opened 2026-05-21
Trial Details
NCT Number NCT07473323
Lead Sponsor Mediar Therapeutics
Conditions Healthy Adult Participants, Diabetic Kidney Disease
Enrollment 88 participants
Start Date 2026-05-19
Primary Completion 2027-05 (estimated)
Study Completion 2028-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-29